Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates

Abstract

The fluoroquinolones have an established role in treatment of infection with aerobic gram negative rods. The increased importance of gram positive nosocomial infection and of acquired fluoroquinolone resistance has stimulated a search for new compounds with enhanced potency and spectrum. CP-99,219 is a novel compound in this class with enhanced activity against gram positive organisms. We have studied the activity of CP-99,219 relative to ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using test panels of organisms with a high proportion of ciprofloxacin resistance. CP-99,219 is more potent than any of the other four compounds against both gram positive and gram negative bacteria. The activity of CP-99,219 against many bacteria resistant to the established agents, warrants further in vitro and clinical studies.

Pharmacokinetics of [ 18 F]Trovafloxacin in Healthy Human Subjects Studied with Positron Emission Tomography

“…Trovafloxacin also has high potency against anaerobic organisms (3,4,37,44) and activity against members of the Enterobacteriaceae (5,42). In general, trovafloxacin has greater potency (MIC at which 90% of the isolates are inhibited [MIC 90 ], Ͻ2 g/ml) and a broader antimicrobial spectrum than ciprofloxacin, temafloxacin, sparfloxacin, fleroxacin, and ofloxacin (6,17,31,42,43). Organisms for which the MIC 90 s of trovafloxacin are Ͼ4 g/ml are rare and include Pseudomonas aeruginosa, Bacteroides fragilis, Staphylococcus haemolyticus, and oxacillin-resistant Staphylococcus aureus.…”